NCT02675543

Brief Summary

The inflammatory response after prolonged retinal detachment and after vitreoretinal surgery has its apex in the development of PVR that occurs when retinal cells are exposed to the inflammatory milieu in the humor vitreous. This situation is common in complicated retinal detachment, but is amplified after invasive surgery and by the use of intraocular tamponades that float over a subtle film of liquid where the inflammatory cytokines and growth factors reach the critical concentration over the inferior retina. Many authors have noted that the heavy tamponade are more prone to cause intraocular inflammation compared to standard silicone oil, especially if they remain for several months in the eye. The purpose of this study is to measure the vitreous concentration of some of the most important cytokines involved in the inflammatory vitreal response.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2015

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 25, 2016

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 5, 2016

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

June 2, 2017

Completed
Last Updated

June 2, 2017

Status Verified

May 1, 2017

Enrollment Period

6 months

First QC Date

January 25, 2016

Results QC Date

May 1, 2017

Last Update Submit

May 1, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Vitreous Prostaglandin E2 Levels

    intraoperarive

Study Arms (2)

Standard silicone oil

EXPERIMENTAL

after vitreous removal, the vitreous chamber was filled with standard silicone oil (PDMS)

Device: Vitreous Tamponade with Silicone Oil

Heavy silicone oil

EXPERIMENTAL

after vitreous removal, the vitreous chamber was filled with heavy silicone oil (Densiron 68)

Device: Vitreous Tamponade with Silicone Oil

Interventions

Heavy silicone oilStandard silicone oil

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patient scheduled for vitrectomy

You may not qualify if:

  • diabetic retinopathy
  • uveitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Schwartz SG, Flynn HW Jr, Wang X, Kuriyan AE, Abariga SA, Lee WH. Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy. Cochrane Database Syst Rev. 2020 May 13;5(5):CD006126. doi: 10.1002/14651858.CD006126.pub4.

Results Point of Contact

Title
Francesco Semeraro
Organization
University of Brescia

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
To Compare Vitreous Inflammation in Standard Versus Heavy Silicone Oil

Study Record Dates

First Submitted

January 25, 2016

First Posted

February 5, 2016

Study Start

June 1, 2015

Primary Completion

December 1, 2015

Last Updated

June 2, 2017

Results First Posted

June 2, 2017

Record last verified: 2017-05